Nuvation Bio Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on events occurring on September 3, 2024, regarding Nuvation Bio Inc.'s 2024 Annual Meeting of Stockholders and subsequent corporate actions. The filing details the voting results of five proposals and changes to the Board of Directors and capital structure.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and equity structure events.
Material Changes and Voting Results
Stockholders representing 92.83% of Class A and 100% of Class B common stock voted on five proposals:
- Proposal 1 (Election of Directors): Min Cui, Ph.D. (Class A) and W. Anthony Vernon (Class B) were elected. Min Cui received 210,137,812 votes "For" with 20,585,212 broker non-votes.
- Proposal 2 (Ratification of Auditors): KPMG LLP was ratified with 231,131,143 votes "For".
- Proposal 3 (Executive Compensation): Advisory approval of named executive officer compensation passed with 208,479,505 votes "For".
- Proposal 4 (Preferred Stock Conversion): Stockholders approved the conversion of Series A Non-Voting Convertible Preferred Stock to Class A Common Stock to comply with NYSE listing rules. The vote was 179,742,172 "For" (excluding shares from the AnHeart Therapeutics acquisition for NYSE rule compliance).
- Proposal 5 (Adjournment): Approval to adjourn the meeting to solicit additional proxies passed with 222,804,900 votes "For".
Management Commentary, Risks, and Unusual Items
Board Leadership Changes: Immediately following the Annual Meeting, David Hung, M.D., was appointed Chair of the Board. Robert B. Bazemore, Jr. was appointed Lead Independent Director. New committee appointments were made for the Audit, Compensation, and Nominating and Corporate Governance committees.
Capital Structure Change: On September 4, 2024, 851,202 shares of Series A Non-Voting Convertible Preferred Stock automatically converted into 85,120,200 shares of Class A Common Stock. Following this conversion, the company has no outstanding preferred stock. The total outstanding shares are now 333,780,289 Class A Common Stock and 1,000,000 Class B Common Stock.
Investor Verification Checklist
- Verify the updated total share count of 333,780,289 Class A shares and 1,000,000 Class B shares post-conversion.
- Confirm the new Board composition, specifically David Hung as Chair and Robert B. Bazemore, Jr. as Lead Independent Director.
- Review the definitive proxy statement filed on July 30, 2024, for detailed executive compensation data referenced in Proposal 3.
- Monitor the impact of the Series A conversion on future dilution and NYSE listing compliance.